Special issue of Future Medicinal Chemistry explores advances in neurodegenerative disease therapy

June 23, 2017

Future Medicinal Chemistry, a leading MEDLINE indexed journal for medicinal chemists, has published two Special Focus issues on Medicinal Chemistry Advances in Neurodegenerative Disease Therapy.

The World Health Organization estimated that in April 2016 there were 47.5 million people suffering from dementia worldwide and by 2050 this number could triple to a predicted 135.5 million. Despite the efforts of a huge number of research groups around the globe, at present, all neurodegenerative diseases are incurable with only palliative treatments available. Driven by this large and increasing need for new therapies in the field, the journal has come together with renowned experts to deliver this Special Focus issue.

The two Special Focus issues have been guest edited by Maria Laura Bolognesi (University of Bologna, Italy) who provided a scene-setting Foreword in the first issue, and commented, "It seems perfectly logical that we should leave no stone unturned in the fight against neurodegenerative diseases and pursue any drug discovery approach that looks promising. In this context, this special issue, which spans various approaches directed to various neurodegenerative diseases, is very timely and germane to current challenges."

The Special Focus issues contain a variety of content including editorial, review and research articles looking at the challenges in neurodegenerative disease therapy. The issue covers neurodegeneration as a whole, as well as Alzheimer's and Parkinson's disease individually. Topics range from investigating inhibition of amyloid oligomerization to targeting neuroregeneration as a therapeutic strategy.

"I am delighted to have worked with experts from around the globe to produce this timely and comprehensive two-part Special Focus Issue discussing the challenges, advancements and potential therapeutics in neurodegenerative disease," stated Rachel Coleby, Commissioning Editor of Future Medicinal Chemistry.
-end-
To celebrate the release of the Special Focus issues, members of our online community MedChemNet will receive free access to the content from both issues throughout the month of July. Sign up to MedchemNet for free here.

To read Part I of the Special Focus Issue on Advances in Neurodegenerative Disease Therapy, please click here -http://www.future-science.com/toc/fmc/9/8

To read Part II of the Special Focus Issue on Advances in Neurodegenerative Disease Therapy, please click here -http://www.future-science.com/toc/fmc/9/10

Future Science Group

Related Neurodegenerative Diseases Articles from Brightsurf:

Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseases
Researchers from the Institut national de la recherche scientifique (INRS) have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases.

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.

Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.

Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

Read More: Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.